Trial record 47 of 139 for:    johnstown

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02063997
First received: February 12, 2014
Last updated: May 20, 2015
Last verified: May 2015
  Purpose
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.

Condition Intervention Phase
Gout
Drug: Arhalofenate 600 mg
Drug: Allopurinol 300 mg
Drug: Colchicine 0.6 mg
Drug: Placebo
Drug: Arhalofenate 800 mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Resource links provided by NLM:


Further study details as provided by CymaBay Therapeutics, Inc.:

Primary Outcome Measures:
  • The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Proportion of patients experiencing at least one flare from baseline through Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients experiencing two or more flares from baseline through Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • The incidence of flares from baseline through Week 4, from Week 5 through Week 8, and from Week 9 through Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Duration of flares [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Duration of flare treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Flare composite score (summation of the daily maximum pain score on NRS during the duration of the flare) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients experiencing flares who reached a sUA target < 6 mg/dL during treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Evaluation of activity limitation associated with flare via HAQ-II [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in fractional excretion of urate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in HbA1c and fasting TG in patients with HbA1c > 7.0% and TG > 150 mg/dL at baseline, respectively [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Adverse events (AE), and changes in vital signs and safety laboratory tests [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Safety-related study drug discontinuations [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Flare-related study drug discontinuations [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Steady-state arhalofenate acid serum and urine concentrations [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 248
Study Start Date: March 2014
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arhalofenate 600 mg Drug: Arhalofenate 600 mg
Arhalofenate 600 mg tablets once daily for 12 weeks
Experimental: Arhalofenate 800 mg Drug: Arhalofenate 800 mg
Arhalofenate 800 mg tablets once daily for 12 weeks
Active Comparator: Allopurinol 300 mg; colchicine 0.6 mg Drug: Allopurinol 300 mg
Allopurinol 300 mg tablets once daily for 12 weeks
Drug: Colchicine 0.6 mg
Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
Active Comparator: Allopurinol 300 mg Drug: Allopurinol 300 mg
Allopurinol 300 mg tablets once daily for 12 weeks
Placebo Comparator: Placebo Drug: Placebo
Placebo tablets once daily for 12 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients between 18 and 75 years of age, inclusive
  • Known gout diagnosis (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout, see Appendix 3)
  • At least three patient-reported and documented flares during the 12 months prior to screening (the first of these flares may have resulted in the gout diagnosis; any recent flare must have resolved, with the patient back to usual comfort level at least seven days prior to screening)
  • Have not used any ULT since at least two weeks prior to screening
  • Have not used colchicine since at least two weeks prior to screening
  • Usual level of resting pain when NOT experiencing flare is three or less on an 11-point numerical rating scale (NRS)
  • Have a sUA ≥ 7.5 mg/dL and ≤ 12 mg/dL at screening
  • All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least two years); or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see Appendix 4) for the entire duration of study participation unless she reports complete sexual abstinence. Female patients must not be pregnant or lactating
  • Estimated creatinine clearance (eCrCl) ≥ 60 ml/min/1.73m2 calculated by Cockcroft-Gault method at screening
  • Liver function tests ≤ 3X ULN for AST, ALT and total bilirubin; ≤ 3X ULN for ALP and GGT; and ≤ 3X ULN for CK at screening
  • All other clinical laboratory parameters must be within normal limits or considered not clinically significant
  • Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant at screening
  • Systolic blood pressure ≤ 160 mm Hg and diastolic blood pressure ≤ 90 mm Hg at screening; known hypertensive patients stable (blood pressure [BP] reading as above) with medication may be included
  • Patients using agents known to influence sUA levels (see Appendix 7) must be on a stable dose and regimen for at least two weeks prior to screening and must be willing to continue the same doses and regimens during study participation
  • Expected to be able to tolerate a short course of either oral NSAIDs and/or oral steroids as may be needed to treat a flare
  • Must be able to swallow tablets/capsules
  • Following training, must be willing and able to understand and complete an electronic diary

Exclusion Criteria:

  • Receiving treatment with allopurinol, colchicine, probenecid, benzbromarone, or febuxostat within two weeks or pegloticase within six months prior to screening
  • Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder or organ transplant)
  • Diagnosis of xanthinuria
  • Fractional excretion of urate > 10% at screening
  • History of documented or suspected kidney stones
  • Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
  • A diagnosis of illicit drug or alcohol dependence or abuse within one year of screening
  • History of upper gastrointestinal (GI) bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), within three years of screening
  • History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI), congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within five years of screening
  • History of cancer within five years of screening, with the following exceptions: adequately treated non-melanomatous skin cancers, non-metastatic prostate cancer or in situ cervical cancer
  • Patients with a history of bladder cancer, active bladder cancer or hematuria
  • Body mass index (BMI) > 42 kg/m2 at screening
  • Current or expected requirement for anticoagulant therapy (except for aspirin ≤ 325 mg/day, clopidogrel [Plavix] ≤ 75 mg/day, or prasugrel [Effient] ≤ 10 mg/day)
  • Use of any of the following within eight weeks prior to screening: potent CYP3A4 inhibitors, cytotoxic agents (including azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.), ranolazine, digoxin, theophylline, sulphonylureas, thiazolidinediones (e.g., rosiglitazone or pioglitazone), atypical antipsychotic agents, ampicillin, amoxicillin, loop diuretics or phenytoin
  • Chronic treatment with NSAIDs (except for as needed [prn] use to treat acute events); per protocol a short course of oral NSAIDs may be used to treat flares during the study
  • Current or expected chronic treatment with systemic corticosteroids (topical, ophthalmic, intra-articular or inhaled corticosteroid at a dose < 1600 μg/day is permitted); per protocol a short course of oral corticosteroid may be used to treat flares occurring during the study
  • History of intra-articular steroid injection to treat flare within four weeks of screening
  • Known hypersensitivity or intolerance to allopurinol or colchicine
  • Treatment with any other investigational therapy within 30 days or within five half lives, whichever is longer, prior to screening
  • Patients who received arhalofenate in a previous trial
  • Any other condition(s) that would compromise the safety of the patient, prevent compliance with the study protocol including ability to use an electronic diary, or compromise the quality of the clinical study, as judged by the Investigator and/or Medical Monitor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02063997

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Scottsdale, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
El Cajon, California, United States
Long Beach, California, United States
Los Angeles, California, United States
United States, Colorado
Denver, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Clearwater, Florida, United States
DeLand, Florida, United States
Jupiter, Florida, United States
New Port Richey, Florida, United States
Orlando, Florida, United States
Palm Harbor, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Idaho
Boise, Idaho, United States
United States, Indiana
Brownsburg, Indiana, United States
United States, Kentucky
Bowling Green, Kentucky, United States
Elizabethtown, Kentucky, United States
Louisville, Kentucky, United States
Owensboro, Kentucky, United States
United States, Maryland
Hagerstown, Maryland, United States
United States, Mississippi
Olive Branch, Mississippi, United States
United States, Missouri
St. Louis, Missouri, United States
United States, Montana
Missoula, Montana, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New York
Brooklyn, New York, United States
New York, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Hickory, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Johnstown, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
Greer, South Carolina, United States
Summerville, South Carolina, United States
United States, Tennessee
Bristol, Tennessee, United States
Jackson, Tennessee, United States
United States, Texas
Houston, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
West Jordan, Utah, United States
United States, Washington
Spokane, Washington, United States
United States, West Virginia
Clarksburg, West Virginia, United States
Canada, Ontario
Newmarket, Ontario, Canada
Sarnia, Ontario, Canada
Toronto, Ontario, Canada
Georgia
Tbilisi, Georgia
Sponsors and Collaborators
CymaBay Therapeutics, Inc.
  More Information

Responsible Party: CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02063997     History of Changes
Other Study ID Numbers: CB102-21425 
Study First Received: February 12, 2014
Last Updated: May 20, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Georgia: Ministry of Health

Additional relevant MeSH terms:
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Allopurinol
Colchicine
Uric Acid
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 25, 2016